PRISM Research Studies

Study that aims to evaluate the effectiveness of the O₂matic PRO100—a closed-loop, autonomous oxygen titration system—in maintaining normoxemia (oxygen saturation of 90–96%) in non-mechanically ventilated patients in acute care. This study aims to confirm the system’s reliability, efficiency, and practicality in real-world settings.

Study quantifying blood pressure change when patients with narcolepsy are treated with high sodium oxybate then transitioned to XYWAV, a low sodium oxybate. The goal of this study is to improve provider care by providing new information on changes in blood pressure related to narcolepsy treatment.

Immune modulation trial comparing early intensification of immune modulation (patients on low flow oxygen) with the study treatment abatacept and standard of care, versus a placebo and standard of care, on outcomes of patients hospitalized with COVID-19.

Public health observational study evaluating the efficacy of both COVID-19 vaccines on the prevention of COVID-19 hospitalizations, and influenza vaccines on the prevention of influenza hospitalizations.

Observational study evaluating the implementation of evidence-based ICU care and the associated effect on the outcomes of patients with ARDS who have been admitted to the ICU and mechanically ventilated.

Observational study that aims to better understand variation across in-hospital cardiac arrest and post-resuscitation care. This study focuses specifically on temperature control and neuroprognostication approaches.

Phase III study on the efficacy and safety of reparixin compared to standard care on limiting disease progression in adult patients hospitalized with community acquired pneumonia (including COVID-19). Efficacy will be measured by recovery, ventilator free days, and mortality.

Phase II study on the efficacy and safety of reparixin in adult patients hospitalized with moderate to severe ARDS, with the goal of improving lung injury and inflammation and decreasing time spent on mechanical ventilation. Each participant will receive ARDS standard care and be assigned to either reparixin or a placebo.

Phase II-like trial comparing a combination treatment of oseltamivir and baloxavir, versus a standard treatment of oseltamivir and a placebo, on outcomes of patients with influenza.

Study evaluating the efficacy and safety of combined hemodialysis with the GARNET™ device. Participants consist of chronic hemodialysis patients who have a blood stream infection and will receive two sessions of hemodialysis with the GARNET™ device.

Study comparing the efficacy of two standard care preoxygenation methods: non-invasive positive pressure ventilation and facemask oxygen. This study aims to better understand the effectiveness of these two methods in order to improve provider care and patient outcomes.

Study investigating the plasma pharmacokinetics and safety of intravenous administration of a single dose (400mg or 600mg) of the study treatment RO7223280 in critically ill patients with bacterial infections.

ACTIV 1: Evaluated different immunomodulatory treatments on speed of recovery, mortality, and illness severity in hospitalized COVID-19 patients. Learn More ↗

ACTIV 2: Evaluated safety and efficacy of infused and non-infused therapeutics in COVID-19 outpatients. Learn More ↗

ACTIV 3b: Evaluated host-tissue treatments in hospitalized COVID-19 patients experiencing acute respiratory failure. Learn More ↗

ACTIV 4a & 4c: Evaluated antithrombotic and prophylactic anticoagulation therapies to prevent illness progression and mortality in hospitalized COVID-19 patients. ACTIV 4a ↗ | ACTIV 4c ↗

ACTIV 4d (NECTAR): Evaluated host tissue response modulators under the Master Host Tissue Protocol in hospitalized COVID-19 patients. Learn More ↗